Stay ahead of cytokine storm by integrating IL-6 into your COVID-19 testing protocol

Key inflammation biomarker now available on Siemens Healthineers immunoassay systems**

Cytokine storm is a dysregulated systemic immune response to infection associated with severe COVID-19 disease, with potential to cause widescale cellular and organ tissue damage. Lab testing can help clinicians identify patients with SARS-CoV-2 infection who are currently experiencing a severe inflammatory response that may indicate development of a cytokine storm.

Get the Literature Compendium now

The role of IL-6 in COVID-19 testing

Infographic on testing for key inflammation markers in COVID-19 patients

The Interleukin-6 (IL-6) assay is an important tool that can assist in identifying severe inflammatory response in patients with confirmed COVID-19 illness to aid in determining the risk of intubation with mechanical ventilation, in conjunction with clinical findings and the results of other laboratory testing. It is an early indicator of inflammatory response to illness or injury. An important mediator of the immune response to pathogens, IL-6 is a member of the cytokine class of chemical messengers that induces both pro- and anti-inflammatory responses. It plays a significant role in the development and escalation of CS in COVID-19 patients.1-3

The integration of IL-6 into COVID-19 testing protocols can help clinicians stay ahead of cytokine storm by assisting in the identification of severe inflammatory response in patients with confirmed COVID-19 illness to aid in determining the risk of intubation with mechanical ventilation, when used in conjunction with clinical findings.

The Siemens Healthineers IL-6 assay is available across the U.S. on the ADVIA Centaur® XP, XPT and CP Systems. Outside the U.S., the IL-6 assay is available with the CE mark on the ADVIA Centaur® Systems, Atellica® IM Analyzer and IMMULITE® Systems.

Learn more about the role of IL-6 in COVID-19-induced cytokine storm syndrome.

Get the Literature Compendium today.

*Required

Clinical performance

Data from 136 symptomatic COVID-19 patients who presented at a US hospital ED were used to assess clinical performance. Confirmation of SARS-CoV-2 infection was based on RT-PCR results.

Using a cut-off value of 35 pg/mL to predict the need for mechanical ventilation the ADVIA Centaur XP IL-6 assay correctly identified 30 of the 35 patients that required intubation.

  • Sensitivity: 85.7% (95% CI = 70.6% to 93.7%)
  • Specificity:64.4% (95% CI = 84.3% to 96.9%)
  • Positive predictive value: 45.5% (95% CI = 34.0% to 57.4%)
  • Negative predictive value: 92.9% (95% CI = 84.3% to 96.9%)
  • Prevalence of mechanical ventilation in COVID-19 confirmed, hospitalized patients: 25.7% (35/136).

IL-6 is just one way Siemens Healthineers can help you care for COVID-19 patients.

Learn more about our broad diagnostics portfolio that aids in the prognosis, treatment, and follow-up of COVID-19 patients, including high-quality total antibody, IgG antibody, and molecular SARS-CoV-2 tests.

Our broad, differentiated menu includes hematology, coagulation, cardiac, respiratory, inflammation, and infectious disease panels. Blood gas and imaging solutions deliver actionable results that aid clinicians in caring for COVID-19 patients.

1

2

3